Clinical Trial Goal
To find out if ruxolitinib is safe and works well to treat HES or primary eosinophilic disorders
You may be able to join this trial if you:
- Are 18 years old or older
- Have HES or primary eosinophilic disorders. Some examples include:
- Chronic eosinophilic leukemia
- Lymphocyte-variant hypereosinophilia
- JAK2-rearranged eosinophilic neoplasm
- Have not been treated with ruxolitinib or other JAK inhibitors. Your doctor can tell you this
- Do not plan to have a blood or marrow transplant (BMT) within the first 6 months of the trial
- Agree to have other standard tests done to see if you can be in the clinical trial
Trial Details
Ruxolitinib is a small molecule inhibitor that blocks JAK1 and JAK2 in certain cells.
You’ll get treatment in cycles that last a month. In each cycle, you'll get:
You’ll get treatment in cycles that last a month. In each cycle, you'll get:
- Ruxolitinib – Given as a pill that you take by mouth 2 times each day
You may continue treatment for up to 6 months. You'll have biopsies and/or scans to see how well the treatment is working. The clinical trial doctors will check your health for up to 3 years.
The Food and Drug Administration (FDA) has approved ruxolitinib to treat polycythemia vera and myelofibrosis. Using it to treat HES or primary eosinophilic disorders is new and unproven.
Locations
Stanford Cancer Institute Palo AltoRECRUITING
Palo Alto, California
Contacts:
- William E Shomali, 650-498-6000, wshomali@stanford.edu
- William E Shomali
OHSU Knight Cancer InstituteTERMINATED
Portland, Oregon
University of UtahTERMINATED
Salt Lake City, Utah
Fred Hutchinson cancer research centerTERMINATED
Seattle, Washington
Sponsors
collaborator: Incyte Corporation, lead: William Shomali
